SIG
LUCD icon

Sargent Investment Group’s Lucid Diagnostics LUCD Stock Holding History

Sargent Investment Group’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$62.1K Hold
54,030
– – 0.01% 264
2025
Q4 		$58.9K Hold
54,030
– – 0.01% 257
2025
Q3 		$54.6K Hold
54,030
– – 0.01% 119
2025
Q2 		$53.5K Buy
54,030
+10,530
+24% +$13.6K 0.01% 233
2025
Q1 		$64.8K Sell
43,500
-498,000
-92% -$598K 0.01% 228
2024
Q4 		$442K Buy
+541,500
New +$478K 0.07% 142

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Sargent Investment Group's LUCD Position: Q1 2026 in Review

Sargent Investment Group held its Lucid Diagnostics (LUCD) position steady in Q1 2026 at 54,030 shares worth $62.1K. The position accounts for 0.01% of the portfolio, ranked #264.

Sargent Investment Group first reported a position in LUCD in Q4 2024 and has held it in 6 quarters since. The position peaked at $442K in Q4 2024. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Sargent Investment Group held 54,030 shares of Lucid Diagnostics worth $62.1K as of Q1 2026.
  • Sargent Investment Group left its Lucid Diagnostics share count unchanged in Q1 2026.
  • Lucid Diagnostics made up 0.01% of Sargent Investment Group's portfolio in Q1 2026, its #264 holding.
  • Sargent Investment Group first reported a position in Lucid Diagnostics in Q4 2024 and has held it in 6 quarters since.
  • Sargent Investment Group's Lucid Diagnostics position peaked at $442K in Q4 2024.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Sargent Investment Group's 13F filing for Q1 2026, filed 11 May 2026.